Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens

REFERENCES

• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/guidelines. February 12,2013.
   Google Scholar
• Maggiolo F. Efavirenz: A decade of clinical experi-ence in the treatment of HIV. J Antimicrob Chemother. 2009;64:910–928.
   PubMed Web of Science ®Google Scholar
• Waters L, Fisher M, Winston A, et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS. 2011;25:65–71.
   PubMed Web of Science ®Google Scholar
• Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57–65.
   PubMed Web of Science ®Google Scholar
• Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsy-chiatric symptoms associated with efavirenz: Prevalence, correlates, management. A neurobehavioral review. AIDS Rev. 2009;11:103–109.
   PubMed Web of Science ®Google Scholar
• Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuro-psychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007;6:147–154.
   PubMed Web of Science ®Google Scholar
• Hawkins T, Geist C, Young B, et al. Comparison of neu-ropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005;6(4)1 87–196.
   Web of Science ®Google Scholar
• Zaccarelli M, Soldani F, Liuzzi G, et al. CNS side effects as main risk factor for efavirenz failure and transient HIV-RNA elevation [abstract 720-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportu-nistic Infections (CR01); February 24–28, 2002; Seattle, Washington. Abstract 720. Alexandria, VA: Foundation for Retrovirology and Human Health; 2002.
   Google Scholar
• Mathias A, Menning M, Wei X, Dave A, Chuck S, Kearney BP. Bioequivalence of the co-formulation of emtricitabine/rilpiv-irine/tenofovir DF. Presented at: XVIII International AIDS Con-ference; July 18–23, 2010; Vienna, Austria. Abstract LBPE17.
   Google Scholar
• Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials. AIDS. 2013;27(6):939–950.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtric-itabine/tenofovir DF: Pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(3):81–91.
   PubMed Web of Science ®Google Scholar
• Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. US Prescribing Information. Foster City, CA: Gilead Sciences, Inc; June 2013.
   Google Scholar
• Eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fuma-rate) tablets. EMA Prescribing Information. Stockley Park, UK: Gilead Sciences, Inc; January 2013.
   Google Scholar
• Thompson M, Aberg J, Hoy J, et al. Antiretroviral treat-ment of adult HIV infection. 2012 Recommendations of the International AIDS Society-USA Panel. JAMA. 2012;308(4):387–402.
   PubMed Web of Science ®Google Scholar
• British HIV Association. BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. http://www.bhiva.org/ClinicalGuidelines.aspx. Accessed September 13, 2013.
   Google Scholar
• White K, Van Eygen V, Vingerhoets J, et al. Week 96 resistance analysis of the pooled ECHO and THRIVE Truvada subset in treatment-naïve HIV-infected adults with ≤100,000 c/mL baseline viral load. In: Program and abstracts of the 18th Annual Conference of the British HIV Association (BHIVA); April 18–20, 2012; Birmingham, UK. Abstract P187.
   Google Scholar
• Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D. Pharmacokinetic parameters of once-daily TMC278 fol-lowing administration of EFV in healthy volunteers. In: Pro-gram and abstracts of the18th Conference on Retroviruses and Opportunistic Infections (CR01); February 27 - March 2, 2011; Boston. Abstract 630.
   Google Scholar
• Boffito M, Jackson A, Lamorde M, et al. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volun-teers. J Acquir Immune Defic Syndr. 2009;52(2):222–227.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clear-ance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Division of Acquired Immune Deficiency Syndrome (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 1. December 28, 2004. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_AduIt_Pediatric_Adverse_Events.pdf. Accessed September 13, 2013.
   Google Scholar
• Fisher M, Palella F, Tebas P, et al. SPIRIT: Switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppres-sion through Week 48. Presented at: 11th International Congress on Drug Therapy in HIV Infection. November 11–15, 2012; Glasgow, UK. Abstract P285.
   Google Scholar
• Martinez E, Larrousse M, Llibre J, et al. Substitution of raltegravir for ritonavir-boosted protease inhibi-tors in HIV-infected patients: The SPIRAL study. AIDS. 2010;24(11):1697–1707.
   PubMed Web of Science ®Google Scholar
• Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted ate-zanavir in patients with virological suppression receiving a LPV/r-containing HAART: The ATAZIP study. J Acquir Immune Defic Syndr. 2009;51(1):29–36.
   PubMed Web of Science ®Google Scholar
• Martinez E, Amaiz J, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349(11):1036–1046.
   PubMed Web of Science ®Google Scholar
• Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral ther-apy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN Study (A1424-097) 48-week results. Clin Infect Dis. 2007;44(11):1484–1492.
   PubMed Web of Science ®Google Scholar
• Alexander H, Seneviratne K, Kamuntu Y, et al. Rilpivirine in clinical practice. In: Program and abstracts of the19th Annual Conference of the British HIV Association (BHIVA); April 16–19, 2013; Manchester, UK. Abstract P147.
   Google Scholar
• Phillips M, Saxon C, McBrien B, et al. Eviplera 1 year on: Experience of a large teaching hospital. In: Program and abstracts of the 19th Annual Conference of the British HIV Association (BHIVA); April 16–19, 2013; Manchester, UK. Abstract P156.
   Google Scholar
• Taylor R, Darley A, Jayasuriya A. Early experience of rilpi-virine use in a medium sized HIV cohort. In: Program and abstracts of the 19th Annual Conference of the British HIV Association (BHIVA); April 16–19, 2013; Manchester, UK. Abstract P163.
   Google Scholar